Results Twenty-eight studies investigating the metabolome of preeclampsia in a variety of biospecimens were identified. Individual metabolite and metabolite profiles were reported to have discriminatory ability to distinguish preeclamptic from normal pregnancies, both prior to and post diagnosis. Lipids and carnitines were among the most commonly reported metabolites. Further work and validation studies are required to demonstrate the utility of such metabolites as preeclampsia biomarkers. Conclusion Metabolomic-based biomarkers of preeclampsia have yet to be integrated into routine clinical practice. However, metabolomic profiling is becoming increasingly popular in the study of preeclampsia and is likely to be a valuable tool to better understand the pathophysiology of this disorder and to better classify its subtypes, particularly when integrated with other omic data.
3
86 Page 2 of 20 in their etiology and manifestations. EO-PE is thought to result from impaired trophoblastic invasion of the maternal spiral arteries and tends to have increased severity and higher incidence of fetal growth restriction. LO-PE appears to be more closely related to pre-existing maternal vascular disorders and other medical comorbidities (Bahado-Singh et al. 2012) . However, emerging evidence suggests additional subtypes or endotypes (subtype defined by a distinct functional or pathobiological mechanism) may co-exist within these classifications (Leavey et al. 2016) . Management and the study of preeclampsia are further complicated by its close relationship to a number of other pregnancy related disorders. In order to tolerate a genetically incompatible fetus, pregnant women undergo complex physiological changes. However in addition to allowing her to carry a child, these adaptions can render her insulin resistant, thrombophilic, immunosuppressed, hypervolemic and dislipidemic (Kaaja and Greer 2005) . This state may manifest as preeclampsia, but can also lead to gestational hypertension, gestational diabetes, or cardiovascular disorder. Similarly preeclampsia and other pregnancy complications are inextricably linked with pre-term birth (Ananth et al. 2006) .
Currently, the pathology of preeclampsia, its differing subtypes and endotypes, and its relationships to other pregnancy complications are not fully understood, there are no validated predictive biomarkers of preeclampsia, few therapeutic options exist, and delivery remains the only definitive cure. Novel approaches are required for the study, prediction, diagnosis, classification, management and treatment of this condition (Navaratnam et al. 2013) .
Widespread alterations in metabolite levels have been demonstrated to precede the clinical onset of preeclampsia, and to continue with the progression of the disorder . Consequently metabolomics, the study of all the small molecule metabolites in a biological sample, may be able to characterize these metabolic differences, inform on the biology underlying them and identify novel preeclampsia biomarkers. Metabolomics is also uniquely placed to identify different endotypes of this condition (Comhair et al. 2015) , and to distinguish it from other pregnancy complications. This review aims to summarize the current literature in an effort to gain a better understanding of the potential role of metabolomics in the study and management of preeclampsia.
Methods
PubMed and Web of Science were searched for studies focusing on the metabolomics of preeclampsia using the following terms; (preeclampsia) AND ((metabolomic*) OR (metabonomic*) OR (metaboli* profil*) OR (metaboli* fingerprint)) ( Fig. 1 ). Studies were eligible for inclusion if the primary aim or outcome was the identification of Women undergoing cesarean section due to: PE (n = 8), Intrauterine growth restriction (n = 6), fetal distress/failed labor (n = 6), self-selection (n = 5), UK Placenta plus matched myometrium from three other groups undergoing cesarean section Baig et al. (2013) Denotes metabolites not otherwise found to be significant by the study in question after employing the most stringent p-value 
Results

Selected studies
Twenty-eight studies focusing on the metabolomics of preeclampsia were identified (Table 1 ). All were published between 2004 and 2017. Eleven studies compared metabolic profile of preeclampsia cases with controls before diagnosis, and 17 after diagnosis. Sixteen studies stated that these comparisons were in order to identify biomarkers of preeclampsia (Table 2) , the reaminder where focussed on distinguishing groups according to their metabolomic profile (Table 3) . Results were presented as either all preeclampsia, or stratified by EO-PE or LO-PE. The studies were not entirely independent; Kuc et al. (2014) and Koster et al. (2015) were based on the same population of 667 women; Turner et al. (2007 Turner et al. ( , 2008 on the same 21 women; Kenny et al. (2005 Kenny et al. ( , 2008 sampled from the same prospective study; and the Bahado-Singh et al. (2015) used the same population as their 2012 study, with the addition of 30 cases and 60 controls for validation purposes. All studies utilized unaffected pregnancies as controls. Blood plasma was the most commonly used biologic media (n = 10) (Bahado-Singh et al. 2012; De Oliveira et al. 2012; Kelly et al. 2016a, b; Kenny et al. 2005 Kenny et al. , 2010 Odibo et al. 2011; Pinto et al. 2015; Schott et al. 2012; Turner et al. 2007 Turner et al. , 2008 , followed by serum (n = 7) (Bahado-Singh et al. 2013 Chen et al. 2017; Kenny et al. 2008; Koster et al. 2015; Kuc et al. 2014) , and placental or intrauterine tissue samples (n = 7) (Austdal et al. 2015a, b; Baig et al. 2013; Dunn et al. 2012; Jain et al. 2004; Korkes et al. 2014; Pearson et al. 2010; Sohlberg et al. 2014) . The remaining studies used urine (n = 1) (Diaz et al. 2013) , urine and serum (n = 2) (Austdal et al. 2014 (Austdal et al. , 2015a , or breast milk (n = 1) (Dangat et al. 2016) . Sixteen studies performed metabolic profiling with mass spectrometry (MS), while 12 used a form of nuclear magnetic resonance spectroscopy (NMR). Ten studies were targeted or semi-targeted to the measurement of specific groups of metabolites (Baig et al. 2013; Braekke et al. 2007; Jain et al. 2004; Koster et al. 2015; Kuc et al. 2014; Odibo Pearson et al. 2010; Pinto et al. 2014; Schott et al. 2012; Sohlberg et al. 2014) . The number of metabolites measured differed according to the choice of technology and approach. The minimum number of metabolites for inclusion in the review was five (Sohlberg et al. 2014) , while as many as 8000 features, as defined by their mass (mz) and retention time (rt) were included in the untargeted studies (Kelly et al. 2016a, b) . Of the prospective studies and nested case-control studies, seven analyzed first trimester metabolites (Austdal et al. 2015a, b; Bahado-Singh et al. 2012 Koster et al. 2015; Kuc et al. 2014; Odibo et al. 2011) , while only three analyzed second trimester metabolites (Diaz et al. 2013; Kenny et al. 2010; Pinto et al. 2014) (Fig. 2) .
Comparison of metabolomics profiles prior to diagnosis
Preeclampsia
Seven studies compared metabolomic profiles of biological samples between controls and cases of any time of onset (Austdal et al. 2015a, b; Diaz et al. 2013; Kelly et al. 2016a, b; Kenny et al. 2010; Koster et al. 2015; Kuc et al. 2014; Odibo et al. 2011) . Lactate was consistently shown to be decreased in the blood of women who went on to develop preeclampsia, while histidine was consistently increased. Risk of the subsequent development of preeclampsia was also associated with an increase in triglycerides, lipids, phospholipids, and fatty acids in serum and in plasma (Austdal et al. 2015a, b; Kelly et al. 2016a, b; Kenny et al. 2010) . Various carnitines were reported as significant (p < 0.05) in four studies spanning serum, plasma and urine (Diaz et al. 2013; Kenny et al. 2010; Koster et al. 2015; Odibo et al. 2011) , although with inconsistent directions of effect. Similarly, urinary measures of hippurate were associated with an increased risk of preeclampsia in the study of Diaz et al. (2013) , but a decreased risk in Austdal et al.'s 2015 study (Austdal et al. 2015a, b) . Among the studies that developed predictive models, the most accurate was Kenny et al. (2010) , which, after validation, used 34 metabolites measured in plasma to generate a PLS-DA model with R 2 and Q 2 values of 0.57 and 0.53, respectively. Further testing with ROC curve analysis determined the area under the curve (AUC) was 0.95. The lowest accuracy was produced by a combination of triglycerides, 3-hydroxybutyrate, pyruvate, phosphatidylcholine, and lactose measured in serum, yielding an accuracy of 64.6, 63.8% sensitivity, and 65.4% specificity (Austdal et al. 2015a, b) . Austdal et al. (2015a, b) compared the ability of metabolomic biomarkers to improve upon traditionally used biomarkers of preeclampsia; a combination of mean arterial pressure (MAP), maternal age, and uterine artery pulsatility index (UtAPI) resulted in a model with an AUC of 0.738, which increased to 0.807 when including the ratio of hippurate to creatinine in urine. Similarly, Kelly et al. (2016) reported that the inclusion of a summary score based on 72 plasma metabolites significantly outperformed a baseline model including maternal age and race, study site, and gestational age (AUC: 0.573 vs. AUC: 0.753).
Early-onset preeclampsia
Five studies investigated EO-PE (Bahado-Singh et al. 2012 Koster et al. 2015; Kuc et al. 2014; Pinto et al. 2014) , three of which were targeted to specific metabolite classes; amines and oxylipins (Kuc et al. 2014) , acylcarnitines (Koster et al. 2015) and phospholipids (Pinto et al. 2014 ). Bahado-Singh et al. validated a number the serum metabolites from their 2013 study (2013) in a 2015 follow up study (Bahado-Singh et al. 2015) , including increased levels of propylene glycol and 3-hydroxyisovalerate and decreased levels of formate, choline, 3-hydroxyisovalerate, succinate, phenylalanine, glycerol, glycine, glucose, isopropanol, and acetate.
In a separate plasma-based study Bahado-Singh et al. (2012) concluded that the addition of three metabolites; 3-hydroxyisovalerate,citrate and glycerol, improved the predictive ability of a clinical panel including parity, uterine artery pulsatility index (UtAPI), fetal crown rump length, and maternal medical history, reporting an AUC of 0.98. Interestingly, only one of these metabolites; 3-hydroxyisovalerate was among those validated in the serum based studies noted above. Conversely, Kuc et al. (2014) and Koster et al. (2015) noted little to no improvement in the prediction of EO-PE with the inclusion of taurine and asparagine or acylcarnitines, compared to maternal characteristics (MAP, pregnancy-associated plasma protein A and placental growth factor) alone.
Late-onset preeclampsia
Three studies also reported on LO-PE, and all were serum based (Bahado-Singh et al. 2013; Koster et al. 2015; Kuc et al. 2014) . Again, carnitine levels were increased in women who went on to develop LO-PE (Bahado-Singh et al. 2013; Koster et al. 2015) . However, Koster et al. (2015) observed that the inclusion of stearoylcarnitine in a predictive risk model provided only an incremental improvement over the clinical risk evaluation based on maternal clinical characteristics and mean MAP. Similarly Kuc et al. (2014) determined that these clinical indices were more effective predictors of LO-PE risk than metabolomic profiling. However, Bahado-Singh et al. (2013) reported a model with an AUC of 0.96, 76.7% sensitivity and 100% specificity, using a combination of valine, pyruvate, 3-hydroxybutyrate, 1-methylhistidine, glycerol, trimethylamine (a downstream metabolite of carnitine) and maternal characteristics.
Overlap between the predictive metabolites
Despite the potential differences in the pathophysiology of EO-PE as compared to LO-PE, a large number of metabolites appeared to be associated with both subtypes. Among those, the levels of carnitines, glucose, pyruvate, 3-hydroxyisovalerate, glycine and their related metabolites were consistently associated with both late and early onset preeclampsia as compared to normal pregnancy in blood and urine, and were also identified in studies that did not stratify by the timing of onset. This may reflect the fact that these two subtypes likely share some underlying biological mechanisms, or more crucially support the hypothesis that classification by age at onset cannot capture all the nuanced subtypes and endotypes of preeclampsia (Leavey et al. 2016) . Conversely, glycerol, isopropanol, and trimethylamine were linked to both EO-PE and LO-PE; but with differing directions of effect, which is in agreement with Bahado-Singh et al.'s (2013) finding that serum levels of glycerol, trimethylamine, and succinate were significantly different when comparing early-and late-onset preeclamptic pregnancies.
Comparison of metabolomic profiles post-diagnosis
Preeclampsia
Seventeen studies compared metabolomic profiles between cases and controls either at or post diagnosis (Austdal et al. 2014 (Austdal et al. , 2015a Braekke et al. 2007; Dunn et al. 2012; Kenny et al. 2005 Kenny et al. , 2008 Schott et al. 2012; Turner et al. 2007 Turner et al. , 2008 . Phospholipids, lipoproteins (n = 5) (Austdal et al. 2014; Dunn et al. 2012; Korkes et al. 2014; Schott et al. 2012; Turner et al. 2007) , creatinine (n = 2) (Braekke et al. 2007; Kenny et al. 2008) , histidine (n = 2) (Austdal et al. 2014; Turner et al. 2008) , glutamate-related metabolites (n = 2) (Austdal et al. 2015a, b; Kenny et al. 2008) , glycine-related metabolites (n = 2) (Austdal et al. 2014 Dunn et al. 2012), and alanine-related metabolites (n = 3) (Dunn et al. 2012; Kenny et al. 2008; Turner et al. 2008) were all significant (p < 0.05) in at least two studies. Increased creatinine, alanine, and phenylalanine levels were consistently associated with preeclampsia, while glycine, glutamate, and glutamine levels were inversely associated. Opposite directions of effect were reported for histidine in plasma as opposed to serum (Austdal et al. 2014; Turner et al. 2008) . Interestingly, amino acid concentrations have previously been shown to correlate poorly across serum and plasma, relative to other metabolite classes (Yu et al. 2011 ). The association with lipids was similarly inconclusive; Schott et al. (2012) reported no significant change in the total amount of phospholipids between the two groups, which was supported by Jain et al. (2004) but both proposed there may be an alteration in the overall lipid profile. The studies searching for biomarkers reported impressive AUCs. The most accurate diagnostic model was developed in placental tissue; it included glycerophosphocholine (GPC), phosphocholine (PCho), aspartate, ascorbate, ethanolamine (EtAm), taurine, glutamate, and glycine, and produced an AUC of 0.927, with a sensitivity of 87%, and a specificity of 98% (Austdal et al. 2015a, b) . While phosphatidylcholine (14:0/00) measured in serum had an AUC of 0.935 (Chen et al. 2017) . Another study reported an AUC, sensitivity and specificity of 0.900, 90% and 100% respectively using a combination of urinary choline, creatine, and glycine (Austdal et al. 2014) . Kenny et al. (2005) achieved 100% sensitivity and 98% specificity with a combination of three unnamed metabolite peaks in plasma. Finally, Dangat et al. (2016) determined using PLS-DA that a combination of seven metabolites in breast milk could discriminate cases from controls even up to 6 months after delivery (R 2 = 0.93, Q 2 = 0.61).
Early-onset preeclampsia
Only two studies focused on early-onset preeclampsia, both of which were targeted to the study of lipid metabolism (De Oliveira et al. 2012; Sohlberg et al. 2014) . Sohlberg et al. (2014) were able to detect increases in phosphodiesters (PDE) and phosphomonoesters (PME) in the placental tissue of EO-PE cases. De Oliveira et al. (2012) did not quantify their results, but stated that good resolution could be achieved using partial least squares discriminant analysis (PLS-DA) and plasma lipid profiles.
Other comparisons
To date, only one study, by Braekke et al. (2007) , has compared = metabolomic profiles of early-and late-onset PE cases. Unlike Bahado-Singh et al.'s (2013) predictive study in serum referenced above, Braekke et al. reported that early-and late-onset PE could not be distinguished based on a plasma metabolomic profile, and furthermore the profile could not distinguish cases by severity. However, it should be noted these studies utilized samples conducted at different time points and are not necessarily comparable. Austdal et al. (2015b) , who conducted their study in placenta, were able to classify individuals by severity using the first principal component of 25 metabolites, including aspartate, phosphocholine, glycerophosphocholine, glutamate, ascorbate, glutamine and taurine. Interestingly, taurine was also identified to be predictive of EO-PE in Kuc et al.'s study (2014) , the more severe manifestation of disease, potentially due to its role in placenta trophoblast development and survival (Desforges et al. 2013 ).
Similarities between metabolomics profiles prior and post-diagnosis
Identifying metabolites that ae altered in preeclamptic women both before and at diagnosis provides important information on the clinical continuum and how early before the onset of clinical symptoms the disease may be manifesting. P-cresol sulfate (n = 2 studies) (Austdal et al. 2014; Diaz et al. 2013) , stearoylcarnitine (n = 2) (Dunn et al. 2012; Koster et al. 2015) , glycine and related metabolites (n = 3) (Austdal et al. 2014 (Austdal et al. , 2015a Dunn et al. 2012) , and lactate and related metabolites (n = 3) (Austdal et al. 2015a, b; Diaz et al. 2013; Turner et al. 2007 ) were decreased both before and during the clinical manifestation of preeclampsia. Similarly, creatinine (n = 4) (Austdal et al. 2015a, b; Braekke et al. 2007; Diaz et al. 2013; Kenny et al. 2008) , alanine (n = 3) (Kenny et al. 2008 (Kenny et al. , 2010 Odibo et al. 2011) , histidine-related metabolites (n = 4) (Austdal et al. 2014 (Austdal et al. , 2015a Diaz et al. 2013; Turner et al. 2008) , dimethylamine (n = 3) (Austdal et al. 2014 (Austdal et al. , 2015a Kelly et al. 2016a, b) , and vitamin D derivatives (n = 2) (Dunn et al. 2012; Kenny et al. 2010) were increased. The findings of Pinto et al. (2014) also suggest that alterations in lipid metabolism associated with EO-PE can be detected as early as the second trimester and persist for the duration of the pregnancy. The consistency of metabolites found in studies using biological samples extracted both pre-and postdiagnosis suggests that the metabolic alterations detected at diagnosis may have been present in the earlier stages of the affected pregnancy.
Discussion
Comparisons with other conditions
As noted in the introduction, preeclampsia is closely linked to a number of other adverse disorders of pregnancy, complicating the definition of preeclampsia endotypes. In assessing the utility of metabolomics both for understanding underlying biology and identifying biomarkers, it is important to determine whether the observed changes in the metabolome are specific to preeclampsia. Austdal et al. (2014) attempted to define a metabolome of uncomplicated pregnancy and determined that a number of the aforementioned 'preeclampsia metabolites,' including alanine, choline, and lactate, also differ in pregnant women compared to non-pregnant controls. Further, it has been demonstrated that the metabolome changes throughout pregnancy; a previous comparison of amniotic fluid and maternal plasma identified 21 metabolites that were significantly different between second and third trimester samples from healthy pregnancies (Orczyk-Pawilowicz et al. 2016) . Again these included several 'preeclampsia metabolites' such as carnitine, creatinine, pyruvate, glucose, alanine, and phenylalanine. Crucially, these did not include lipid mediators, which may therefore be more sensitive biomarkers of the inflammatory process in preeclamptic pregnancies. Several of the included studies in this review also considered other adverse pregnancy outcomes. Austdal et al. (2015) identified predictive biomarkers of gestational hypertension, which included dimethylamine (DMA), phenylacetylglutamine (PAG), and alanine in the urine, and triglycerides, high density lipoprotein (HDL) cholesterol, lactate, N-acetyl glycoproteins, phosphatidylcholine, and glucose in serum; all of which have been implicated in preeclampsia. Similarly, Diaz et al. (2013) analyzed the urinary metabolomic profiles of women with gestational diabetes mellitus (GDM) and was able to identify several metabolic trends common to both GDM and preeclampsia, including decreases in lactose, glycine, creatinine, and an increase in glucose (Bahado-Singh et al. 2012 Diaz et al. 2013) . Diaz et al. (2013) also demonstrated considerable overlap between metabolites associated with preterm birth (PD) (delivery <37 weeks of gestation) and preeclampsia including an increase in 3-hydroxybutyrate (Austdal et al. 2015a, b; Bahado-Singh et al. 2013) , citrate (Bahado-Singh et al. 2013; Diaz et al. 2013) , and histidine (Austdal et al. 2014; Turner et al. 2008) . Baig et al. (2013) reported that dysregulation of lipid metabolism was evident in the placental syncytiotrophoblast microvesicles of women with preeclampsia and those with recurrent miscarriage relative to controls, and specifically that levels of sphingomyelin and phosphatidylserine were increased while phosphatidylinositol. Similarly Pearson et al. (2010) observed dysregulation of vasoactive metabolites in women undergoing cesarean due to preeclampsia or a growth restricted pregnancy, relative to elective cesareans. These findings are not unexpected given the strong correlation between these disorders and preeclampsia, and further work is required to disentangle the shared and distinct metabolic dysregulation underlying these conditions, and particularly the role that lipid metabolism may be playing.
Obesity is an established risk factor for preeclampsia (Poston et al. 2016) . Accordingly, there is significant overlap in the metabolites highlighted for these two conditions. Hippurate has previously been associated with obesity in a number of metabolomics studies, which may relate to compositional differences in the gut microbiome associated with BMI (Lees et al. 2013 ). Other preeclampsia metabolites including triglycerides, lipids, phospholipids, and fatty acids (Austdal et al. 2015a, b; Kelly et al. 2016a, b; Kenny et al. 2010 ) comprise a well-known metabolomic signature of immune dysfunction and systemic low-grade inflammation (Ruiz-Núñez et al. 2016) which is a key feature of obesity induced dyslipidemia. Carnitines and fatty acid metabolism are also associated with obesity (Wahl et al. 2012) through the exertion of immune regulatory functions supported predominantly by carnitine-dependent energy production from fatty acids (Famularo et al. 2004; Ruiz-Núñez et al. 2016) .
Alterations to carnitine and fatty acid metabolism has been demonstrated in a wide range of other idiopathic inflammatory disorders and in cardiovascular disease (Famularo et al. 2004; Ruiz-Núñez et al. 2016 ). Similar to obesity, the literature suggests very high concordance between the cardiovascular and preeclampsia associated metabolites. Intriguingly there is also evidence that both obesity and cardiovascular disease share a similar genetic architecture to preeclampsia (Sitras et al. 2015) . Carnitines have further been associated with blood pressure and hypertension unrelated to pregnancy (Miguel-Carrasco et al. 2008) , as have 3-hydroxyisovalerate (Jennings et al. 2016) , hippurate (Lees et al. 2013 ) and glycine (Currie et al. 2013) , among others. Again these relationships are likely due to various roles of these metabolites in oxidative stress, inflammation and immune dysregulation.
Interestingly, there are also a number of similarities between the metabolites identified in the preeclampsia studies and those identified in studies of asthma including acetate, adenosine, alanine, hippurate, succinate, threonine and trans-aconitate, as well as pathways relating to hypoxia response, oxidative stress, immunity, inflammation and lipid metabolism (Kelly et al. 2016a, b) . These relationships may help explain the recently reported association between preeclampsia and risk of asthma in the offspring (Stokholm et al. 2016 ) and further suggests shared pathophysiology between the two disorders.
Methodological considerations
Two differing technologies were utilized by the identified studies; Mass-spec and NMR. Each has advantages and disadvantages NMR spectroscopy is quantitative and requires less intensive sample preparation making it more reproducible between studies, while MS is inherently more sensitive allowing for the detection of a much larger number of metabolites (Emwas 2015) . The complement of metabolites measured by these two methods are not necessarily comparable. In this review this is further complicated by the hypothesis-driven targeted approach taken in a number of the studies, limiting the potential for replication and validation. Interestingly, no study employed both technologies on the same sample, yet combining the two may provide the greatest opportunity to develop robust and accurate metabolomic profiles of preeclampsia. The chosen technology also dictated the reporting of results to an extent. The level of quantitative detail varied between the studies, and a number of the non-biomarker studies (De Oliveira et al. 2012; Jain et al. 2004; Korkes et al. 2014; Pearson et al. 2010; Schott et al. 2012; Sohlberg et al. 2014; Turner et al. 2007 Turner et al. , 2008 did not report effect sizes for individual or groups of metabolites, but rather commented on general trends observed in the results. This was particularly common among the NMR studies which often reported spectral regions rather than actual metabolites. This limits the utility of these findings in understanding biology, although they do serve as further supportive evidence for the overarching conclusion that the preeclamptic metabolome, as measured in a variety of biological samples, differs from that of a healthy pregnancy.
As the placenta is the interface between mother and baby, metabolomic profiling of the placenta and related intrauterine tissues may provide some of the most biologically informative findings, and some of the strongest findings were reported for placenta based studies (Austdal et al. 2015a, b) . Unfortunately, due to its relative inaccessibility for the duration of the pregnancy, most studies can only sample placental and intrauterine tissue following delivery. Only one study included ultrasound information about the placenta in the third trimester, but even then, observation was limited to anterior placentas due to technical limitations (Sohlberg et al. 2014) . Furthermore, because metabolites identified in the later stages of pregnancy cannot be assumed to correspond to those detected in earlier trimesters, these metabolites may only generate hypotheses for future investigations into their predictive and diagnostic merit. In contrast, blood and urine are considerably more accessible and have greater potential for clinical translation. The discriminatory ability was largely comparable between these different bio specimens in the included studies. It should be noted that it has been reported that measures of metabolites in plasma may be more reproducible that serum due to the less intensive sample preparation requirements (Yu et al. 2011) . However, it is unclear based on these studies which specimen type is most ideal for identifying metabolomic biomarkers of preeclampsia and how specimen choice influences findings.
Regardless of the bio-specimen used, he metabolome is dynamic and reflects both the endogenous and exogenous metabolites present in the body at a given point in time. As such, it is highly susceptible to the influence of age, diet, BMI, comorbidities and other unknown factors. Matching was used in a number of studies to address potential confounding factors. However, regardless of matched status, significant epidemiological differences between cases and controls were noted in many studies for factors that may have influenced the findings such as race (Bahado-Singh et al. 2013 Odibo et al. 2011) , maternal weight or BMI (Kelly et al. 2016a, b; Turner et al. 2007 Turner et al. , 2008 , fetal birth weight (Austdal et al. 2015a, b; Braekke et al. 2007; Kenny et al. 2005; Odibo et al. 2011; Sohlberg et al. 2014) , history of hypertension (Koster et al. 2015; Kuc et al. 2014) , parity (Austdal et al. 2015a, b; Koster et al. 2015; Kuc et al. 2014) , UtAPI (Austdal et al. 2014; BahadoSingh et al. 2012 BahadoSingh et al. , 2015 Sohlberg et al. 2014) , MAP (Austdal et al. 2014), gestational age (Austdal et al. 2015a, b; Braekke et al. 2007; Koster et al. 2015; Odibo et al. 2011) , smoking status (Koster et al. 2015; Kuc et al. 2014) , fetal growth restriction (FGR) (Austdal et al. 2015a, b) , and/or maternal age (Austdal et al. 2015a, b) . In particular, differences in maternal BMI were shown to influence findings in some studies (Turner et al. 2007 (Turner et al. , 2008 . Race may also have an important effect due to the higher risk of preeclampsia that has been reported among Black and Hispanic women (Tanaka et al. 2007) . Five studies described the racial breakdown by percentage (Bahado-Singh et al. 2012 Kelly et al. 2016a, b; Odibo et al. 2011) , and two studies did not report the cohort's ethnicity, but mentioned that it was adjusted for in the final analysis (Kenny et al. 2005; Kuc et al. 2014 ). Many studies included majority Caucasian populations (Austdal et al. 2014 (Austdal et al. , 2015a De Oliveira et al. 2012; Kenny et al. 2008 Kenny et al. , 2010 Korkes et al. 2014; Turner et al. 2007) , which may have implications for the wider generalizability of the findings. Nevertheless the existence of additional, unexplored confounding factors including diet, vitamin supplementation, medication use, exercise, stress, or other medical disorders cannot be ruled out.
Additional biases and inconsistences in results may arise from technical factors related to sample collection and laboratory procedures. Such factors can add to the inherent ''noisiness" of metabolomic data. Only seven studies reported on quality control procedures (Braekke 2007; Dunn et al. 2012; Kelly et al. 2016a, b; Kenny et al. 2010; Korkes et al. 2014; Koster et al. 2015; Kuc et al. 2014) , and only seven corrected for multiple comparisons (Austdal et al. 2014 (Austdal et al. , 2015a Bahado-Singh et al. 2015; Koster et al. 2015; Kuc et al. 2014; Turner et al. 2007 Turner et al. , 2008 . Furthermore, only two reported power calculations (Bahado-Singh et al. 2013; Odibo et al. 2011) . Thirteen studies sought to validate their results through additional testing, including internal cross validation (Austdal et al. 2014 (Austdal et al. , 2015a BahadoSingh et al. 2012 BahadoSingh et al. , 2013 BahadoSingh et al. , 2015 Chen et al. 2017; Diaz et al. 2013) , partitioning of data into a training and test set (Bahado-Singh 2015; Kenny et al. 2005; Koster et al. 2015; Kuc et al. 2014) , assessing a signature developed in first trimester samples in third trimester samples (Kelly et al. 2016a, b) , or verification in an independent cohort (Kenny et al. 2010) . Additionally, two of the studies were designed to validate previously published results (Bahado-Singh et al. 2015; Kenny et al. 2008) . Validation is particularly important for the correct interpretation of PLS-DA which tends to over-fit data. Two studies failed to present evidence of PLS-DA validation (De Oliveira et al. 2012; Pinto et al. 2014 ), although De Oliveira et al. (2012 does state that the use of PLS-DA was not to assess predictive ability, but rather to confirm significant metabolites. Furthermore, Pinto et al. (2014) only report Q 2 values, which provides an estimate of prediction, but no indication of significance, and caution should be taken with the interpretation of such studies. It should also be noted that the human metabolome remains incompletely characterized. Only two studies reported specific un-annotated metabolites (Diaz et al. 2013; Kelly et al. 2016a, b) . If these un-annotated metabolites were associated with disease, their omission could introduce bias to the biological interpretation of the findings.
Finally, it should be noted that a number of these studies are very limited by sample size with seven studies including less than ten preeclampsia cases in any one study group (Baig et al. 2013; De Oliveira et al. 2012; Diaz et al. 2013; Dunn et al. 2012; Jain et al. 2004; Pearson et al. 2010; Pinto et al. 2014) . Such studies are likely underpowered, although biologically relevant results in keeping with some of the larger studies were reported. Nevertheless, more weight should be given to the larger well-designed studies. The largest studies contained a total of 167 cases (Koster et al. 2015; Kuc et al. 2014) , and interestingly although these studies identified serum steroylcarnitine and taurine as potential predictive biomarkers they concluded at present metabolomics-based assays are not suitable for preeclampsia. Larger studies such as the ongoing multi-center IMPROvED (improved pregnancy outcomes via early detection) (Navaratnam et al. 2013 ) study, which aims to recruit 5000 pregnant women in order to develop predictive metabolomic and proteomic signatures of preeclampsia, are required.
Conclusion
Metabolomics is a rapidly emerging field in preeclampsia that has the potential to address some of the biggest challenges in the management of this disorder; the development of biomarkers, the identification of endotypes and an increased understanding of pathogenesis. The published literature to date suggests metabolomics may be able to fulfill this potential with the identification of biologically meaningful metabolites and metabolomics profiles that can distinguish preeclamptic from normal pregnancies in a variety of biosamples both prior and post diagnosis.
A summary of all identified metabolites can be seen in Table 4 . The findings were reasonably consistent between studies, with lipids and carnitines among the most commonly highlighted metabolites. The results support the existence of a preeclampsia metabolome that is characterized largely by dysregulated fatty acid metabolism, which can be measured in a variety of biological samples, including blood, urine, placental tissue and breast milk. Even more intriguingly, these results suggest that the plasma metabolome may differ between early and late onset cases which is in agreement with the investigations implicating discriminant pathogenic pathways within these subtypes. But also, that there are likely further as yet unknown subtypes, or endotypes within these classifications. In fact metabolomics is likely to play a key role in defining such endotypes. Similar work has already been performed utilizing transcriptomic profiling in preeclampsia (Leavey et al. 2016) .
In addition to metabolomics, multiple other omic studies have been conducted to try and better understand the molecular mechanisms underlying preeclampsia and to search for novel biomarkers. For example, a placental metasignature that can identify preeclampsia cases has been developed. This was based on differential gene-expression and included genes relating to the pathways of angiogenesis, immunomodulation, vascular function and trophoblast invasion, many of which were also highlighted in this review (Kleinrouweler et al. 2013) . Similarly, almost 120 miRNAs have been reported to be dysregulated in preeclampsia (Jairajpuri and Almawi 2016) . The most consistent being miR-210 which is associated with hypoxia, another process highlighted by the metabolomics studies. Oxidative stress has further been identified as a key process from proteomic studies of preeclampsia (Law et al. 2015) . Multiple other processes identified in this review including dysregulation of lipids, steroidogenesis, membrane function and energy metabolism have also been reported for a number of different omics. Therefore, the most information and the most global understanding of preeclampsia subtypes can likely be garnered by integrating metabolomics with other hierarchical omic levels, and such work should form a key feature of the study of preeclampsia as the field moves forward.
To date, clinical translation of metabolomic biomarkers of preeclampsia has yet to be realized. Additional studies addressing the clinical complexities of preeclampsia, as well as the technical complexities of metabolomic profiling, are required before clinical translation can become a reality. For example appropriate subtyping of preeclampsia, the identification of the ideal biological sample, the role of potential confounders and the best way to harness MS or NMR or both. Furthermore, the issue of parsimony must be taken into account and profiles containing large numbers of metabolites may prove to be unfeasible in a clinical setting. Larger scale studies in diverse populations with comprehensive phenotyping, including multiple biological media, covering a broad and detailed measure of the metabolome and utilizing sophisticated statistical methods that allow for the aforementioned complexities are required. Until such studies are performed, the currently published literature suggests the most important role metabolomic studies of preeclampsia can play will be as tools to begin to better understand preeclampsia pathophysiology, and to better define the subtypes comprising this condition.
